Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login
Market Place

First Subjects Dosing with VS-041 a Novel Heart Failure Treatment services provided by Quotient Sciences

Quotient Sciences
First Subjects Dosing with VS-041 a Novel Heart Failure Treatment
Full Screen View

PDF Upload Sep, 2024

Quotient And Vasa Begin Human Trials Of VS-041 For Novel Heart Failure Therapy

11 Sep 2024

// PRESS RELEASE

Quotient Sciences Wins 2024 CRO Leadership Awards

05 Jun 2024

// PRESS RELEASE

Quotient Sciences Announces New Facility Leadership in Philadelphia, PA

05 Jun 2024

// PRESS RELEASE

DATA COMPILATION
#PharmaFlow

Quotient rm 250x250

Contact Supplier

DDF Summit, US

Attending

Book a meeting now

envelop Contact Supplier

Xls

CATEGORY PAGE

Quotient Sciences

VISIT THE VIRTUAL BOOTH, Contact Details

VISIT THE VIRTUAL BOOTH
Review portfolio & marketing content
CONTACT DETAILS
Google Map, LinkedIn, Emails...

EVENTS

Webinars & Exhibitions

Webinars & Exhibitions

PRESENTATION(s)

Corporate Presentation, First Subjects Dosing with VS-041 a Novel Heart Failure Treatment, 14C Human ADME Program for HTD1801, Oxilio & Quotient Announce Regulatory Approval for OXL001, Expansion of Facilities for Translational Pharmaceutics® Programs, Ensysce Biosciences & Quotient Announce a Partnership, Human ADME Studies, Bioanalytical Services, Translational Pharmaceutics®, Formulation Strategies for Poorly Soluble Molecules, Global Formulation Development & Manufacturing Capabilities, Commercial Manufacturing, Clinical Trial Manufacturing, Global Clinical Trial Supplies, GMP Certificate 2019, Financial Impact of Translational Pharmaceutics®, High Potency Handling, Project Management at Quotient Sciences, Pediatrics Services, Formulation Development, Clinical Pharmacology

Corporate Presentation
First Subjects Dosing with VS-041 a Novel Heart Failure Treatment
14C Human ADME Program for HTD1801
Oxilio & Quotient Announce Regulatory Approval for OXL001
Expansion of Facilities for Translational Pharmaceutics® Programs
Ensysce Biosciences & Quotient Announce a Partnership
Human ADME Studies
Bioanalytical Services
Translational Pharmaceutics®
Formulation Strategies for Poorly Soluble Molecules
Global Formulation Development & Manufacturing Capabilities
Commercial Manufacturing
Clinical Trial Manufacturing
Global Clinical Trial Supplies
GMP Certificate 2019
Financial Impact of Translational Pharmaceutics®
High Potency Handling
Project Management at Quotient Sciences
Pediatrics Services
Formulation Development
Clinical Pharmacology

VIDEO(s)

Corporate Video, Bioanalytical Services, Candidate Molecule Selection, CDMO Solutions for Orphan & Rare Diseases, Early Development, Late Development, Orphan Drug Programs, What is Bioanalysis? (BioA), Our Manifesto, Miami Clinical Pharmacology Facility

Corporate Video
Bioanalytical Services
Candidate Molecule Selection
CDMO Solutions for Orphan & Rare Diseases
Early Development
Late Development
Orphan Drug Programs
What is Bioanalysis? (BioA)
Our Manifesto
Miami Clinical Pharmacology Facility

DIGITAL CONTENT

3 INTERVIEW #SpeakPharma, 31 CORPORATE CONTENT #SupplierSpotlight, 1 DATA COMPILATION #PharmaFlow, 136 NEWS #PharmaBuzz

3 INTERVIEW #SpeakPharma
31 CORPORATE CONTENT #SupplierSpotlight
1 DATA COMPILATION #PharmaFlow
136 NEWS #PharmaBuzz

DEVELOPMENTS

21 Drugs in Development

21 Drugs in Development

SERVICES

Analytical, Clinical Trials, API Manufacturing, Drug Product Manufacturing, API & Drug Product Development, Packaging

Analytical
- 1 BioAnalytical Services
- 1 Analytical Method Development
Clinical Trials
API Manufacturing
Drug Product Manufacturing
API & Drug Product Development
Packaging
- 5 Clinical Services

KEY SERVICES

Pharmacy Compounding Services, Pharmacy Compounding & Formulation Services, Formulation Development of Capsules, Development of Nasal Dosage Forms, CDMO for Suspensions, Pediatric Formulation Development

Pharmacy Compounding Services
Pharmacy Compounding & Formulation Services
Formulation Development of Capsules
Development of Nasal Dosage Forms
CDMO for Suspensions
Pediatric Formulation Development

INSPECTIONS & REGISTRATIONS

6 FDA, 7 EDQM, 1 GDUFA

6 FDA
7 EDQM
1 GDUFA

PI72998

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
LOOKING FOR A SUPPLIER?